Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma

Giorgio Treglia, Paola Castaldi, Maria Felicia Villani, Germano Perotti, Chiara De Waure, Angelina Filice, Valentina Ambrosini, Nadia Cremonini, Monica Santimaria, Annibale Versari, Stefano Fanti, Alessandro Giordano, Vittoria Rufini

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Purpose To retrospectively evaluate and compare 18F-FDG, 18F-DOPA and 68Ga-somatostatin analogues for PET/CT in patients with residual/recurrent medullary thyroid carcinoma (MTC) suspected on the basis of elevated serum calcitonin levels. Methods Included in the study were 18 patients with recurrent MTC in whom functional imaging with the three tracers was performed. The PET/CT results were compared on a per-patient basis and on a per-lesion-basis. Results At least one focus of abnormal uptake was observed on PET/CT in 13 patients with 18F-DOPA (72.2% sensitivity) , in 6 patients with 68Ga-somatostatin analogues (33.3%) and in 3 patients with 18F-FDG (16.7%) (p18F-DOPA and 18F-FDG PET/CT (p18F-DOPAand 68Ga-somatostatin analogue PET/CT (p00.04) . Overall, 72 lesions were identified on PET/CT with the three tracers. 18F-DOPA PET/CT detected 85% of lesions (61 of 72) , 68Ga-somatostatin analogue PET/CT 20% (14 of 72) and 18F-FDG PET/CT 28% (20 of 72) . There was a statistically significant difference in the number of lymph node, liver and bone lesions detected with the three tracers (p18F-DOPA PET/CT and 18F-FDG PET/CT (p18F-DOPA PET/ CT and 68Ga-somatostatin analogue PET/CT (p18F-DOPA PET/CT seems to be the most useful imaging method for detecting recurrent MTC lesions in patients with elevated serum calcitonin levels, performing better than 18F-FDG and 68Ga-somatostatin analogue PET/ CT. 18F-FDG may complement 18F-DOPA in patients with an aggressive tumour.

Original languageEnglish
Pages (from-to)569-580
Number of pages12
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume39
Issue number4
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Fluorodeoxyglucose F18
Somatostatin
Calcitonin
Medullary Thyroid cancer
Serum
Lymph Nodes
Bone and Bones
Liver

Keywords

  • Diagnosis
  • Medullary thyroid carcinoma
  • Neuroendocrine tumours
  • PET/CT
  • Positron emission tomography

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. / Treglia, Giorgio; Castaldi, Paola; Villani, Maria Felicia; Perotti, Germano; De Waure, Chiara; Filice, Angelina; Ambrosini, Valentina; Cremonini, Nadia; Santimaria, Monica; Versari, Annibale; Fanti, Stefano; Giordano, Alessandro; Rufini, Vittoria.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 39, No. 4, 04.2012, p. 569-580.

Research output: Contribution to journalArticle

Treglia, Giorgio ; Castaldi, Paola ; Villani, Maria Felicia ; Perotti, Germano ; De Waure, Chiara ; Filice, Angelina ; Ambrosini, Valentina ; Cremonini, Nadia ; Santimaria, Monica ; Versari, Annibale ; Fanti, Stefano ; Giordano, Alessandro ; Rufini, Vittoria. / Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. In: European Journal of Nuclear Medicine and Molecular Imaging. 2012 ; Vol. 39, No. 4. pp. 569-580.
@article{fbc8268459204ec6a633038a77994ac9,
title = "Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma",
abstract = "Purpose To retrospectively evaluate and compare 18F-FDG, 18F-DOPA and 68Ga-somatostatin analogues for PET/CT in patients with residual/recurrent medullary thyroid carcinoma (MTC) suspected on the basis of elevated serum calcitonin levels. Methods Included in the study were 18 patients with recurrent MTC in whom functional imaging with the three tracers was performed. The PET/CT results were compared on a per-patient basis and on a per-lesion-basis. Results At least one focus of abnormal uptake was observed on PET/CT in 13 patients with 18F-DOPA (72.2{\%} sensitivity) , in 6 patients with 68Ga-somatostatin analogues (33.3{\%}) and in 3 patients with 18F-FDG (16.7{\%}) (p18F-DOPA and 18F-FDG PET/CT (p18F-DOPAand 68Ga-somatostatin analogue PET/CT (p00.04) . Overall, 72 lesions were identified on PET/CT with the three tracers. 18F-DOPA PET/CT detected 85{\%} of lesions (61 of 72) , 68Ga-somatostatin analogue PET/CT 20{\%} (14 of 72) and 18F-FDG PET/CT 28{\%} (20 of 72) . There was a statistically significant difference in the number of lymph node, liver and bone lesions detected with the three tracers (p18F-DOPA PET/CT and 18F-FDG PET/CT (p18F-DOPA PET/ CT and 68Ga-somatostatin analogue PET/CT (p18F-DOPA PET/CT seems to be the most useful imaging method for detecting recurrent MTC lesions in patients with elevated serum calcitonin levels, performing better than 18F-FDG and 68Ga-somatostatin analogue PET/ CT. 18F-FDG may complement 18F-DOPA in patients with an aggressive tumour.",
keywords = "Diagnosis, Medullary thyroid carcinoma, Neuroendocrine tumours, PET/CT, Positron emission tomography",
author = "Giorgio Treglia and Paola Castaldi and Villani, {Maria Felicia} and Germano Perotti and {De Waure}, Chiara and Angelina Filice and Valentina Ambrosini and Nadia Cremonini and Monica Santimaria and Annibale Versari and Stefano Fanti and Alessandro Giordano and Vittoria Rufini",
year = "2012",
month = "4",
doi = "10.1007/s00259-011-2031-6",
language = "English",
volume = "39",
pages = "569--580",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "4",

}

TY - JOUR

T1 - Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma

AU - Treglia, Giorgio

AU - Castaldi, Paola

AU - Villani, Maria Felicia

AU - Perotti, Germano

AU - De Waure, Chiara

AU - Filice, Angelina

AU - Ambrosini, Valentina

AU - Cremonini, Nadia

AU - Santimaria, Monica

AU - Versari, Annibale

AU - Fanti, Stefano

AU - Giordano, Alessandro

AU - Rufini, Vittoria

PY - 2012/4

Y1 - 2012/4

N2 - Purpose To retrospectively evaluate and compare 18F-FDG, 18F-DOPA and 68Ga-somatostatin analogues for PET/CT in patients with residual/recurrent medullary thyroid carcinoma (MTC) suspected on the basis of elevated serum calcitonin levels. Methods Included in the study were 18 patients with recurrent MTC in whom functional imaging with the three tracers was performed. The PET/CT results were compared on a per-patient basis and on a per-lesion-basis. Results At least one focus of abnormal uptake was observed on PET/CT in 13 patients with 18F-DOPA (72.2% sensitivity) , in 6 patients with 68Ga-somatostatin analogues (33.3%) and in 3 patients with 18F-FDG (16.7%) (p18F-DOPA and 18F-FDG PET/CT (p18F-DOPAand 68Ga-somatostatin analogue PET/CT (p00.04) . Overall, 72 lesions were identified on PET/CT with the three tracers. 18F-DOPA PET/CT detected 85% of lesions (61 of 72) , 68Ga-somatostatin analogue PET/CT 20% (14 of 72) and 18F-FDG PET/CT 28% (20 of 72) . There was a statistically significant difference in the number of lymph node, liver and bone lesions detected with the three tracers (p18F-DOPA PET/CT and 18F-FDG PET/CT (p18F-DOPA PET/ CT and 68Ga-somatostatin analogue PET/CT (p18F-DOPA PET/CT seems to be the most useful imaging method for detecting recurrent MTC lesions in patients with elevated serum calcitonin levels, performing better than 18F-FDG and 68Ga-somatostatin analogue PET/ CT. 18F-FDG may complement 18F-DOPA in patients with an aggressive tumour.

AB - Purpose To retrospectively evaluate and compare 18F-FDG, 18F-DOPA and 68Ga-somatostatin analogues for PET/CT in patients with residual/recurrent medullary thyroid carcinoma (MTC) suspected on the basis of elevated serum calcitonin levels. Methods Included in the study were 18 patients with recurrent MTC in whom functional imaging with the three tracers was performed. The PET/CT results were compared on a per-patient basis and on a per-lesion-basis. Results At least one focus of abnormal uptake was observed on PET/CT in 13 patients with 18F-DOPA (72.2% sensitivity) , in 6 patients with 68Ga-somatostatin analogues (33.3%) and in 3 patients with 18F-FDG (16.7%) (p18F-DOPA and 18F-FDG PET/CT (p18F-DOPAand 68Ga-somatostatin analogue PET/CT (p00.04) . Overall, 72 lesions were identified on PET/CT with the three tracers. 18F-DOPA PET/CT detected 85% of lesions (61 of 72) , 68Ga-somatostatin analogue PET/CT 20% (14 of 72) and 18F-FDG PET/CT 28% (20 of 72) . There was a statistically significant difference in the number of lymph node, liver and bone lesions detected with the three tracers (p18F-DOPA PET/CT and 18F-FDG PET/CT (p18F-DOPA PET/ CT and 68Ga-somatostatin analogue PET/CT (p18F-DOPA PET/CT seems to be the most useful imaging method for detecting recurrent MTC lesions in patients with elevated serum calcitonin levels, performing better than 18F-FDG and 68Ga-somatostatin analogue PET/ CT. 18F-FDG may complement 18F-DOPA in patients with an aggressive tumour.

KW - Diagnosis

KW - Medullary thyroid carcinoma

KW - Neuroendocrine tumours

KW - PET/CT

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=84862526634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862526634&partnerID=8YFLogxK

U2 - 10.1007/s00259-011-2031-6

DO - 10.1007/s00259-011-2031-6

M3 - Article

C2 - 22223169

AN - SCOPUS:84862526634

VL - 39

SP - 569

EP - 580

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 4

ER -